| Novo Nordisk A/S is a Denmark-based healthcare company. The Company provides diabetes care and has diabetes product portfolio in the industry, including insulin delivery systems. Novo Nordisk operates on a worldwide basis in two business segments: diabetes care, which includes discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral anti-diabetic products (OAD), and biopharmaceuticals, which includes discovery, development, manufacturing and marketing of products within the therapy areas hemostasis management (NovoSeven), growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas. During the year ended December 31, 2007, it initiated Phase I studies of its long-acting recombinant factor VIIa analogue, a subcutaneous formulation of rFVIIa for the treatment of hemophilia patients with inhibitors and a long-acting human growth hormone. |
